Suppl Figure S1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency

Anirban Das,Uri Tabori, Lauren C. Sambira Nahum,Natalie B. Collins,Rebecca Deyell,Rina Dvir,Cecile Faure-Conter,Timothy E. Hassall,Jane E. Minturn,Melissa Edwards, Elissa Brookes,Vanessa Bianchi,Adrian Levine, Simone C. Stone,Sumedha Sudhaman, Santiago Sanchez Ramirez,Ayse B. Ercan,Lucie Stengs, Jill Chung,Logine Negm,Gad Getz,Yosef E. Maruvka,Birgit Ertl-Wagner,Pamela S. Ohashi,Trevor Pugh,Cynthia Hawkins,Eric Bouffet,Daniel A. Morgenstern

crossref（2023）

引用 0|浏览5

暂无评分

摘要

Pathological complete remission in metastatic colorectal adenocarcinoma. (A) Baseline (hematoxylin-eosin, CD8 and PD-L1). (B) Post-nivolumab: no detectable tumor cells, increased inflammation, and increase in CD8 and PD-L1 expression. All IHC images are 100X.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要